Prothena Corporation plc (NASDAQ:PRTA – Get Free Report) major shareholder William Scully bought 100,000 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were acquired at an average cost of $8.43 per share, with a total value of $843,000.00. Following the completion of the transaction, the insider owned 927,000 shares of the company’s stock, valued at $7,814,610. This represents a 12.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Prothena Price Performance
PRTA opened at $8.68 on Thursday. Prothena Corporation plc has a fifty-two week low of $7.73 and a fifty-two week high of $11.80. The firm has a market capitalization of $454.40 million, a PE ratio of -10.33, a P/E/G ratio of 3.17 and a beta of -0.33. The company’s 50-day moving average is $8.92 and its 200 day moving average is $9.40.
Prothena (NASDAQ:PRTA – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.07. The business had revenue of $1.01 million during the quarter, compared to the consensus estimate of $0.42 million. Prothena had a negative return on equity of 16.45% and a negative net margin of 80.68%. As a group, analysts expect that Prothena Corporation plc will post 0.08 EPS for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on PRTA
Institutional Investors Weigh In On Prothena
Several large investors have recently made changes to their positions in the business. Rubric Capital Management LP boosted its holdings in shares of Prothena by 36.0% in the 1st quarter. Rubric Capital Management LP now owns 5,000,000 shares of the biotechnology company’s stock worth $48,600,000 after buying an additional 1,322,669 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Prothena by 8.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,581,443 shares of the biotechnology company’s stock worth $15,372,000 after buying an additional 123,679 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Prothena by 1.0% in the first quarter. Dimensional Fund Advisors LP now owns 782,603 shares of the biotechnology company’s stock worth $7,606,000 after acquiring an additional 7,396 shares during the period. Renaissance Technologies LLC raised its position in Prothena by 39.5% in the first quarter. Renaissance Technologies LLC now owns 607,515 shares of the biotechnology company’s stock worth $5,905,000 after acquiring an additional 172,000 shares during the period. Finally, Penbrook Management LLC purchased a new position in Prothena in the first quarter valued at about $2,641,000. 97.08% of the stock is owned by hedge funds and other institutional investors.
About Prothena
Prothena Corporation plc (NASDAQ: PRTA) is a clinical-stage biotechnology company focused on discovering and developing novel therapies for neurodegenerative and other protein-misfolding diseases. The company’s research is based on targeting abnormal proteins and the biological processes associated with their accumulation in tissue.
Prothena’s lead programs include birtamimab, an investigational antibody being developed for patients with AL amyloidosis, and prasinezumab, an investigational antibody targeting alpha-synuclein for Parkinson’s disease.
Featured Articles
- Five stocks we like better than Prothena
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.
